Related references
Note: Only part of the references are listed.Evolving role of regorafenib for the treatment of advanced cancers
Axel Grothey et al.
CANCER TREATMENT REVIEWS (2020)
Anti-vimentin, anti-TUFM, anti-NAP1L1 and anti-DPYSL2 nanobodies display cytotoxic effect and reduce glioblastoma cell migration
Alja Zottel et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma
Antonio Silvani et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Proteomic Analysis Implicates Vimentin in Glioblastoma Cell Migration
Michal O. Nowicki et al.
CANCERS (2019)
Glioblastoma endothelium drives bevacizumab-induced infiltrative growth via modulation of PLXDC1
Maria Laura Falchetti et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
Giuseppe Lombardi et al.
LANCET ONCOLOGY (2019)
PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation A Randomized Phase II Study: BrUOG 244
Heinrich Elinzano et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2018)
Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells
Hyangsoon Noh et al.
CANCER LETTERS (2018)
Pre- and early postoperative GFAP serum levels in glioma and brain metastases
Peter Baumgarten et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Alternating electric tumor treating fields for treatment of glioblastoma: rationale, preclinical, and clinical studies
Sandeep Mittal et al.
JOURNAL OF NEUROSURGERY (2018)
A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system
Peter E. Manley et al.
PEDIATRIC BLOOD & CANCER (2018)
High Expression of Vimentin is Associated With Progression and a Poor Outcome in Glioblastoma
Jiaxin Zhao et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2018)
Anti-Angiogenics: Their Role in the Treatment of Glioblastoma
Frank Winkler et al.
ONCOLOGY RESEARCH AND TREATMENT (2018)
Updates in prognostic markers for gliomas
Elisa Aquilanti et al.
NEURO-ONCOLOGY (2018)
Repositioning Microtubule Stabilizing Drugs for Brain Disorders
Artemis Varidaki et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2018)
Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines
Clotilde Thery et al.
JOURNAL OF EXTRACELLULAR VESICLES (2018)
γ-tubulin as a signal-transducing molecule and meshwork with therapeutic potential
Maria Alvarado-Kristensson
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2018)
Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches
Ana Miranda et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2017)
Serum concentrations of glial fibrillary acidic protein (GFAP) do not indicate tumor recurrence in patients with glioblastoma
Julia-Mareen Vietheer et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
Michael Weller et al.
LANCET ONCOLOGY (2017)
Type III Intermediate Filaments Desmin, Glial Fibrillary Acidic Protein (GFAP), Vimentin, and Peripherin
Elly M. Hol et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2017)
Circulating CD9+/GFAP+/survivin plus exosomes in malignant glioma patients following survivin vaccination
Phillip M. Galbo et al.
ONCOTARGET (2017)
Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives
Wojciech Szopa et al.
BIOMED RESEARCH INTERNATIONAL (2017)
Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients
M. Mehta et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma
Julia Tichy et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
An Overview of Alternating Electric Fields Therapy (NovoTTF Therapy) for the Treatment of Malignant Glioma
Kenneth D. Swanson et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2016)
The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells
Raphael Berges et al.
MOLECULAR CANCER THERAPEUTICS (2016)
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2016)
Immunohistochemical expression of stem cell markers CD44 and nestin in glioblastomas: Evaluation of their prognostic significance
Elia Guadagno et al.
PATHOLOGY RESEARCH AND PRACTICE (2016)
Asymmetric Distribution of GFAP in Glioma Multipotent Cells
Pierre-Olivier Guichet et al.
PLOS ONE (2016)
Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients
Lin Lin et al.
TUMOR BIOLOGY (2016)
Discovery of cell surface vimentin targeting mAb for direct disruption of GBM tumor initiating cells
Hyangsoon Noh et al.
ONCOTARGET (2016)
Microtubule targeting agents in glioma
Anda-Alexandra Calinescu et al.
TRANSLATIONAL CANCER RESEARCH (2016)
Phase 1/2 trial of bevacizumab plus TPI 287, a brain penetrable anti-microtubule agent, in patients with recurrent glioblastoma.
Samuel Aaron Goldlust et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Glioblastoma: Overview of Disease and Treatment
Mary Elizabeth Davis
CLINICAL JOURNAL OF ONCOLOGY NURSING (2016)
Glioblastoma: pathology, molecular mechanisms and markers
Kenneth Aldape et al.
ACTA NEUROPATHOLOGICA (2015)
Intermediate filaments in cell migration and invasion: the unusual suspects
Cecile Leduc et al.
CURRENT OPINION IN CELL BIOLOGY (2015)
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma A Randomized Clinical Trial
Roger Stupp et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Stem cell signature in glioblastoma: therapeutic development for a moving target
Ichiro Nakano
JOURNAL OF NEUROSURGERY (2015)
Building the Neuronal Microtubule Cytoskeleton
Lukas C. Kapitein et al.
NEURON (2015)
A practical review of prognostic correlations of molecular biomarkers in glioblastoma
Michael Karsy et al.
NEUROSURGICAL FOCUS (2015)
Roles and Potential Clinical Applications of Intermediate Filament Proteins in Brain Tumors
Quincy Quick et al.
SEMINARS IN PEDIATRIC NEUROLOGY (2015)
Emerging Microtubule Targets in Glioma Therapy
Christos D. Katsetos et al.
SEMINARS IN PEDIATRIC NEUROLOGY (2015)
Characterization of Nestin, a Selective Marker for Bone Marrow Derived Mesenchymal Stem Cells
Liang Xie et al.
STEM CELLS INTERNATIONAL (2015)
Second-Line Chemotherapy in Recurrent Glioblastoma: A 2-Cohort Study
Bruno F. Carvalho et al.
ONCOLOGY RESEARCH AND TREATMENT (2015)
Initial Testing (Stage 1) of BAL101553, a Novel Tubulin Binding Agent, by the Pediatric Preclinical Testing Program
E. Anders Kolb et al.
PEDIATRIC BLOOD & CANCER (2015)
Paclitaxel Poliglumex, Temozolomide, and Radiation for Newly Diagnosed High-grade Glioma A Brown University Oncology Group Study
Suriya Jeyapalan et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2014)
Diagnostic and Prognostic Value of Preoperative Combined GFAP, IGFBP-2, and YKL-40 Plasma Levels in Patients With Glioblastoma
Jaime Gallego Perez-Larraya et al.
CANCER (2014)
Small-molecule clinical trial candidates for the treatment of glioma
Saurabh Prabhu et al.
DRUG DISCOVERY TODAY (2014)
Synemin acts as a regulator of signalling molecules during skeletal muscle hypertrophy
Zhenlin Li et al.
JOURNAL OF CELL SCIENCE (2014)
The Novel Microtubule-Destabilizing Drug BAL27862 Binds to the Colchicine Site of Tubulin with Distinct Effects on Microtubule Organization
Andrea E. Prota et al.
JOURNAL OF MOLECULAR BIOLOGY (2014)
A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC)
Marc C. Chamberlain et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Sustained elevation of Snail promotes glial-mesenchymal transition after irradiation in malignant glioma
Roshan Mahabir et al.
NEURO-ONCOLOGY (2014)
Molecular and cellular heterogeneity: the hallmark of glioblastoma
Diane J. Aum et al.
NEUROSURGICAL FOCUS (2014)
Preclinical profile of cabazitaxel
Patricia Vrignaud et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2014)
Phase I Study of GRN1005 in Recurrent Malignant Glioma
Jan Drappatz et al.
CLINICAL CANCER RESEARCH (2013)
Review on intermediate filaments of the nervous system and their pathological alterations
Claire Lepinoux-Chambaud et al.
HISTOCHEMISTRY AND CELL BIOLOGY (2013)
Astrocytoma grade IV (gLioblastoma multiforme) displays 3 subtypes with unique expression profiles of intermediate filament proteins
Omar Skalli et al.
HUMAN PATHOLOGY (2013)
Glioblastoma and Other Malignant Gliomas A Clinical Review
Antonio Omuro et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model
Ananth K. Vellimana et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
The meaning of the anti-cancer antibody CLN-IgG (Pritumumab) generated by human x human hybridoma technology against the cyto-skeletal protein, vimentin, in the course of the treatment of malignancy
Albert V. Hugwil
MEDICAL HYPOTHESES (2013)
Nestin: A novel angiogenesis marker and possible target for tumor angiogenesis
Yoko Matsuda et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
Targeting βIII-Tubulin in Glioblastoma Multiforme: From Cell Biology and Histopathology to Cancer Therapeutics
Christos D. Katsetos et al.
Anti-Cancer Agents in Medicinal Chemistry (2012)
Epothilone B inhibits migration of glioblastoma cells by inducing microtubule catastrophes and affecting EB1 accumulation at microtubule plus ends
Alessandra Pagano et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Discovery of Small Molecule Inhibitors that Interact with γ-Tubulin
Douglas E. Friesen et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2012)
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality
Roger Stupp et al.
EUROPEAN JOURNAL OF CANCER (2012)
Improved survival time trends for glioblastoma using the SEER 17 population-based registries
Matthew Koshy et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Synemin promotes AKT-dependent glioblastoma cell proliferation by antagonizing PP2A
Aaron Pitre et al.
MOLECULAR BIOLOGY OF THE CELL (2012)
TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells
Daniel P. Fitzgerald et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
Wolfgang Wick et al.
LANCET ONCOLOGY (2012)
Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma
Xinlong Ma et al.
NEURO-ONCOLOGY (2012)
Patupilone (Epothilone B) for Recurrent Glioblastoma: Clinical Outcome and Translational Analysis of a Single-Institution Phase I/II Trial
Christoph Oehler et al.
ONCOLOGY (2012)
Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group
R. Stupp et al.
ANNALS OF ONCOLOGY (2011)
Vimentin in cancer and its potential as a molecular target for cancer therapy
Arun Satelli et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2011)
Inducible expression of stem cell associated intermediate filament nestin reveals an important role in glioblastoma carcinogenesis
Wen Jing Lu et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme
Ren-Yuan Bai et al.
NEURO-ONCOLOGY (2011)
Exciting New Advances in Neuro-Oncology The Avenue to a Cure for Malignant Glioma
Erwin G. Van Meir et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Carboplatin combined with the vascular-disrupting agent CYT997 for recurrent glioblastoma multiforme
J. Lickliter et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma
Michael Brada et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas
David M. Peereboom et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Microtubule-binding agents: a dynamic field of cancer therapeutics
Charles Dumontet et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Microtubules and resistance to tubulin-binding agents
Maria Kavallaris
NATURE REVIEWS CANCER (2010)
OncoGel (ReGel/paclitaxel) - Clinical applications for a novel paclitaxel delivery system
Nancy L. Elstad et al.
ADVANCED DRUG DELIVERY REVIEWS (2009)
2-Methoxyestradiol as a Potential Cytostatic Drug in Gliomas?
E. Kirches et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2009)
Discovery of CYT997: a structurally novel orally active microtubule targeting agent
Christopher J. Burns et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Tubulin Targets in the Pathobiology and Therapy of Glioblastoma Multiforme. II. γ-Tubulin
Christos D. Katsetos et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2009)
Tubulin Targets in the Pathobiology and Therapy of Glioblastoma Multiforme. I. Class III β-Tubulin
Christos D. Katsetos et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2009)
Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas
Antonio Silvani et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Ixabepilone: targeting beta III-tubulin expression in taxane-resistant malignancies
Charles Dumontet et al.
MOLECULAR CANCER THERAPEUTICS (2009)
CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo
Christopher J. Burns et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases
Jens Hoffmann et al.
NEURO-ONCOLOGY (2009)
Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2
A. Regina et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo
Terence O'Reilly et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate
Ulricj Klar et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Intermediate filament protein synemin contributes to the migratory properties of astrocytoma cells by influencing the dynamics of the actin cytoskeleton
Yihang Pan et al.
FASEB JOURNAL (2008)
The prognostic value of nestin expression in newly diagnosed glioblastoma: Report from the Radiation Therapy Oncology Group
Prakash Chinnaiyan et al.
RADIATION ONCOLOGY (2008)
Serum GFAP is a diagnostic marker for glioblastoma multiforme
C. S. Jung et al.
BRAIN (2007)
Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas
T. Brommeland et al.
ACTA NEUROLOGICA SCANDINAVICA (2007)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
Relevance of combinatorial profiles of intermediate filaments and transcription factors for glioma histogenesis
C. Colin et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2007)
MPC-6827: A small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps
Shailaja Kasibhatla et al.
CANCER RESEARCH (2007)
Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors
Eilon D. Kirson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Intermediate filaments: A historical perspective
Robert G. Oshima
EXPERIMENTAL CELL RESEARCH (2007)
The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin
Paola Bargagna-Mohan et al.
CHEMISTRY & BIOLOGY (2007)
Synemin is expressed in reactive astrocytes in neurotrauma and interacts differentially with vimentin and GFAP intermediate filament networks
Runfeng Jing et al.
JOURNAL OF CELL SCIENCE (2007)
Nestin expression in the cell lines derived from glioblastoma multiforme
R Veselska et al.
BMC CANCER (2006)
Intermediate filament protein synemin is present in human reactive and malignant astrocytes and associates with ruffled membranes in astrocytoma cells
RF Jing et al.
GLIA (2005)
Phase 2 study of T138067-sodium in patients with malignant glioma: Trial of the National Cancer Institute of Canada clinical trials group
S Kirby et al.
NEURO-ONCOLOGY (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Microtubules as a target for anticancer drugs
MA Jordan et al.
NATURE REVIEWS CANCER (2004)
Angiogenic endothelium-specific nestin expression is enhanced by the first intron of the nestin gene
M Aihara et al.
LABORATORY INVESTIGATION (2004)
Mechanisms of disease: Intermediate filament proteins and their associated diseases
MB Omary et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Characterisation of benzimidazole binding with recombinant tubulin from Giardia duodenalis, Encephalitozoon intestinalis, and Cryptosporidium parvum
LM MacDonald et al.
MOLECULAR AND BIOCHEMICAL PARASITOLOGY (2004)
Functions of intermediate filaments in neuronal development and disease
RC Lariviere et al.
JOURNAL OF NEUROBIOLOGY (2004)
Collapsin response mediator proteins (CRMPs) - Involvement in nervoust system development and adult neurodegenerative disorders
E Charrier et al.
MOLECULAR NEUROBIOLOGY (2003)
Nestin as a marker for proliferative endothelium in gliomas
K Sugawara et al.
LABORATORY INVESTIGATION (2002)
Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier
SM Rubenstein et al.
JOURNAL OF MEDICINAL CHEMISTRY (2001)
Desmuslin, an intermediate filament protein that interacts with α-dystrobrevin and desmin
Y Mizuno et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000)
LF Eng et al.
NEUROCHEMICAL RESEARCH (2000)
Glioma/glioblastoma-specific adenoviral gene expression using the nestin gene regulator
H Kurihara et al.
GENE THERAPY (2000)
Share Paper
